RepliCel Life SciencesのROCE
RepliCel Life SciencesのROCEは何ですか。
RepliCel Life Sciences, Inc.のROCEは0.00%です。
ROCEの定義は何ですか。
使用資本利益率(ROCE)は、企業の収益性とその資本が使用される効率を測定する財務比率です。
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
TSXVのセクタHealth CareにおけるROCEの企業と比べるRepliCel Life Sciences
RepliCel Life Sciencesは何をしますか。
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
RepliCel Life Sciencesと類似のroce
- Omega Alpha SpacのROCEは-0.01%です。
- The GapのROCEは-0.01%です。
- Elemental Royalties LtdのROCEは-0.01%です。
- Auburn National BancorpのROCEは-0.01%です。
- Galaxy DigitalのROCEは-0.01%です。
- The GapのROCEは-0.01%です。
- RepliCel Life SciencesのROCEは0.00%です。
- Tejon Ranch CoのROCEは0.01%です。
- Glen Burnie BancorpのROCEは0.02%です。
- MSP Steel & PowerのROCEは0.02%です。
- TTL Beteiligungs- und Grundbesitz-AGのROCEは0.03%です。
- First Foundation IncのROCEは0.03%です。
- FirstMark Horizon AcquisitionのROCEは0.03%です。